191 related articles for article (PubMed ID: 22152933)
1. [A simple view on lung cancer biology: the MET pathway].
Ruppert AM; Beau-Faller M; Belmont L; Lavolé A; Gounant V; Cadranel J; Wislez M
Rev Mal Respir; 2011 Dec; 28(10):1241-9. PubMed ID: 22152933
[TBL] [Abstract][Full Text] [Related]
2. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.
Christensen JG; Burrows J; Salgia R
Cancer Lett; 2005 Jul; 225(1):1-26. PubMed ID: 15922853
[TBL] [Abstract][Full Text] [Related]
3. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer.
Yamada T; Matsumoto K; Wang W; Li Q; Nishioka Y; Sekido Y; Sone S; Yano S
Clin Cancer Res; 2010 Jan; 16(1):174-83. PubMed ID: 20008840
[TBL] [Abstract][Full Text] [Related]
4. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer.
De Bacco F; Luraghi P; Medico E; Reato G; Girolami F; Perera T; Gabriele P; Comoglio PM; Boccaccio C
J Natl Cancer Inst; 2011 Apr; 103(8):645-61. PubMed ID: 21464397
[TBL] [Abstract][Full Text] [Related]
5. Targeting the MET oncogene in cancer and metastases.
Stella GM; Benvenuti S; Comoglio PM
Expert Opin Investig Drugs; 2010 Nov; 19(11):1381-94. PubMed ID: 20868306
[TBL] [Abstract][Full Text] [Related]
6. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.
Eder JP; Vande Woude GF; Boerner SA; LoRusso PM
Clin Cancer Res; 2009 Apr; 15(7):2207-14. PubMed ID: 19318488
[TBL] [Abstract][Full Text] [Related]
7. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network.
Webb CP; Hose CD; Koochekpour S; Jeffers M; Oskarsson M; Sausville E; Monks A; Vande Woude GF
Cancer Res; 2000 Jan; 60(2):342-9. PubMed ID: 10667586
[TBL] [Abstract][Full Text] [Related]
8. Involvement of HGF/SF-Met signaling in prostate adenocarcinoma cells: evidence for alternative mechanisms leading to a metastatic phenotype in Pr-14c.
MacDougall CA; Vargas M; Soares CR; Holzer RG; Ide AE; Jorcyk CL
Prostate; 2005 Jul; 64(2):139-48. PubMed ID: 15678502
[TBL] [Abstract][Full Text] [Related]
9. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy.
Li Y; Lal B; Kwon S; Fan X; Saldanha U; Reznik TE; Kuchner EB; Eberhart C; Laterra J; Abounader R
Cancer Res; 2005 Oct; 65(20):9355-62. PubMed ID: 16230398
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
[TBL] [Abstract][Full Text] [Related]
11. Small molecule c-Met kinase inhibitors: a review of recent patents.
Porter J
Expert Opin Ther Pat; 2010 Feb; 20(2):159-77. PubMed ID: 20100000
[TBL] [Abstract][Full Text] [Related]
12. Adenovirus-mediated siRNA targeting c-Met inhibits proliferation and invasion of small-cell lung cancer (SCLC) cells.
Wang ZX; Lu BB; Yang JS; Wang KM; De W
J Surg Res; 2011 Nov; 171(1):127-35. PubMed ID: 20338593
[TBL] [Abstract][Full Text] [Related]
13. Gene of the month: MET.
Skead G; Govender D
J Clin Pathol; 2015 Jun; 68(6):405-9. PubMed ID: 25987653
[TBL] [Abstract][Full Text] [Related]
14. Structure, biosynthesis and biochemical properties of the HGF receptor in normal and malignant cells.
Comoglio PM
EXS; 1993; 65():131-65. PubMed ID: 8380735
[TBL] [Abstract][Full Text] [Related]
15. Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress.
Cui JJ
J Med Chem; 2014 Jun; 57(11):4427-53. PubMed ID: 24320965
[TBL] [Abstract][Full Text] [Related]
16. MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.
Pan BS; Chan GK; Chenard M; Chi A; Davis LJ; Deshmukh SV; Gibbs JB; Gil S; Hang G; Hatch H; Jewell JP; Kariv I; Katz JD; Kunii K; Lu W; Lutterbach BA; Paweletz CP; Qu X; Reilly JF; Szewczak AA; Zeng Q; Kohl NE; Dinsmore CJ
Cancer Res; 2010 Feb; 70(4):1524-33. PubMed ID: 20145145
[TBL] [Abstract][Full Text] [Related]
17. Hepatocyte growth factor exerts multiple biological functions on bovine mammary epithelial cells.
Accornero P; Martignani E; Macchi E; Baratta M
J Dairy Sci; 2007 Sep; 90(9):4289-96. PubMed ID: 17699048
[TBL] [Abstract][Full Text] [Related]
18. Genetic and expression analysis of MET, MACC1, and HGF in metastatic colorectal cancer: response to met inhibition in patient xenografts and pathologic correlations.
Galimi F; Torti D; Sassi F; Isella C; Corà D; Gastaldi S; Ribero D; Muratore A; Massucco P; Siatis D; Paraluppi G; Gonella F; Maione F; Pisacane A; David E; Torchio B; Risio M; Salizzoni M; Capussotti L; Perera T; Medico E; Di Renzo MF; Comoglio PM; Trusolino L; Bertotti A
Clin Cancer Res; 2011 May; 17(10):3146-56. PubMed ID: 21447729
[TBL] [Abstract][Full Text] [Related]
19. The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents.
Robinson KW; Sandler AB
Oncologist; 2013; 18(2):115-22. PubMed ID: 23345546
[TBL] [Abstract][Full Text] [Related]
20. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges.
Liu X; Newton RC; Scherle PA
Trends Mol Med; 2010 Jan; 16(1):37-45. PubMed ID: 20031486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
